Metagenomi, Inc. (MGX)

NASDAQ: MGX · IEX Real-Time Price · USD
11.87
-0.13 (-1.08%)
Feb 28, 2024, 2:35 PM EST - Market open
-1.08%
Market Cap 445.45M
Revenue (ttm) 37.95M
Net Income (ttm) -63.59M
Shares Out 37.53M
EPS (ttm) -1.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 53,887
Open 11.87
Previous Close 12.00
Day's Range 11.79 - 12.10
52-Week Range 9.74 - 12.74
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About MGX

Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using our proprietary, comprehensive metagenomics-derived genome editing toolbox. We are harnessing the power of metagenomics, the study of genetic material recovered from the natural environment, to unlock four billion years of microbial evolution to discover and develop a suite of novel editing tools capable of correcting any type of genetic mutation found anywhere in the genome. Our comprehensive genome editing toolbox includes prog... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 9, 2024
Employees 223
Stock Exchange NASDAQ
Ticker Symbol MGX
Full Company Profile

Financial Performance

Financial Statements

News

Metagenomi Announces Closing of Initial Public Offering

EMERYVILLE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprie...

14 days ago - GlobeNewsWire

Moderna, Bayer-backed Metagenomi stock drops 32% on Nasdaq debut

Shares of Metagenomi Technologies , a genetic medicines company backed by Bayer Healthcare and Moderna , slumped 32% in their Nasdaq debut on Friday.

19 days ago - Reuters

Moderna-backed Metagenomi cuts US IPO valuation target to $563 mln

Genetic medicines company Metagenomi Technologies MGX.O said on Thursday it is aiming for a valuation of $563 million in its U.S. initial public offering (IPO), a number that is at the low end of its ...

19 days ago - Reuters

Metagenomi Announces Pricing of Initial Public Offering

EMERYVILLE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (“Metagenomi”), a precision genetic medicines company committed to developing curative therapeutics for patients us...

19 days ago - GlobeNewsWire

Moderna, Bayer-backed startup Metagenomi files for US IPO

Metagenomi Technologies, a genetic medicines company backed by Bayer Healthcare and Moderna , filed for an initial public offering (IPO) in the United States on Friday.

7 weeks ago - Reuters

Gene editing biotech Metagenomi files for a $100 million IPO

Metagenomi, a preclinical biotech developing therapies using metagenomics-derived genome editing, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

7 weeks ago - Renaissance Capital

Metagenomi IPO Registration Document (S-1)

Metagenomi has filed to go public with an IPO on the NASDAQ.

7 weeks ago - SEC